Inherited retinal diseases: Progress being made with treatment modalities

The delivery of lipid nanoparticle-based mRNA to the retina is encouraging, according to researchers.

Winners of 2023 ARVO research fellowships announced

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.

Finding the clues: What retinal vasculature changes may mean for cognitive impairment

Ultra-widefield imaging may be a promising technology for assessing larger areas of the retinal vasculature to uncover retinal changes in Alzheimer’s disease, according to investigators.

2023: What ophthalmologists in Europe anticipate for the year ahead

December 12, 2022

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

Faricimab approved for treatment of nAMD, DMO by European Commission

September 19, 2022

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Fluid monitor utilises AI to identify, localise and quantify retinal fluid

September 07, 2022

Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.

Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real time

September 06, 2022

According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.